BIOA
BioAge Labs, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.32
P/S
70.12
EV/EBITDA
-5.43
DCF Value
$8.57
FCF Yield
-13.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.2%
Operating Margin
-1031.5%
Net Margin
-896.1%
ROE
-27.9%
ROA
-27.3%
ROIC
-33.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.1M | $-25.9M | $-0.72 |
| FY 2025 | $9.0M | $-80.6M | $-2.24 |
| Q3 2025 | $2.1M | $-20.2M | $-0.56 |
| Q2 2025 | $2.4M | $-21.6M | $-0.60 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.24
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.